O	0	2	Is
O	3	5	it
O	6	15	important
O	16	18	to
O	19	24	adapt
B-intervention	25	36	neoadjuvant
I-intervention	37	49	chemotherapy
O	50	52	to
O	53	56	the
O	57	64	visible
O	65	73	clinical
O	74	82	response
O	82	83	?

O	84	86	An
O	87	91	open
O	92	102	randomized
O	103	108	phase
O	109	111	II
O	112	117	study
O	118	127	comparing
O	128	136	response
O	136	137	-
O	137	143	guided
O	144	147	and
O	148	156	standard
O	157	167	treatments
O	168	170	in
O	171	175	HER2
O	175	176	-
O	176	184	negative
O	185	193	operable
O	194	200	breast
O	201	207	cancer
O	207	208	.

O	209	220	Neoadjuvant
O	221	230	treatment
O	231	239	provides
O	240	241	a
O	242	248	unique
O	249	260	opportunity
O	261	263	to
O	264	272	evaluate
O	273	283	individual
O	284	289	tumor
O	290	301	sensitivity
O	301	302	.

O	303	307	This
O	308	313	study
O	314	323	evaluated
O	324	331	whether
O	332	333	a
O	334	342	response
O	342	343	-
O	343	349	guided
O	350	358	strategy
O	359	364	could
O	365	372	improve
O	373	381	clinical
O	382	389	outcome
O	390	398	compared
O	399	403	with
O	404	405	a
O	406	414	standard
O	415	424	treatment
O	424	425	.

O	426	433	Overall
O	433	434	,
B-total-participants	435	438	264
B-eligibility	439	449	previously
I-eligibility	450	459	untreated
I-eligibility	460	465	stage
I-eligibility	466	468	II
I-eligibility	468	469	-
I-eligibility	469	472	III
I-eligibility	473	481	operable
I-eligibility	482	488	breast
I-eligibility	489	495	cancer
I-eligibility	496	504	patients
O	505	509	were
O	510	520	randomized
O	521	523	to
O	524	531	receive
O	532	538	either
B-control	539	547	standard
I-control	548	557	treatment
O	558	559	(
O	559	562	arm
O	563	564	A
O	564	565	,
O	566	567	n
O	568	569	=
B-control-participants	570	573	131
O	573	574	)
O	574	575	,
O	576	586	consisting
O	587	589	of
O	590	602	fluorouracil
O	602	603	,
O	604	614	epirubicin
O	614	615	,
O	616	619	and
O	620	636	cyclophosphamide
O	637	638	(
O	638	644	FEC100
O	644	645	:
O	646	649	500
O	649	650	,
O	651	654	100
O	654	655	,
O	656	659	and
O	660	663	500
O	664	666	mg
O	666	667	/
O	667	668	m
O	668	669	(
O	669	670	2
O	670	671	)
O	671	672	,
O	673	685	respectively
O	685	686	,
O	687	690	for
O	691	692	3
O	693	699	cycles
O	699	700	)
O	701	709	followed
O	710	712	by
O	713	722	docetaxel
O	723	724	(
O	724	727	100
O	728	730	mg
O	730	731	/
O	731	732	m
O	732	733	(
O	733	734	2
O	734	735	)
O	736	739	for
O	740	741	3
O	742	748	cycles
O	748	749	)
O	749	750	,
O	751	753	or
O	754	761	adapted
O	762	771	treatment
O	772	773	(
O	773	776	arm
O	777	778	B
O	778	779	,
O	780	781	n
O	782	783	=
B-intervention-participants	784	787	133
O	787	788	)
O	788	789	,
O	790	799	beginning
O	800	804	with
O	805	806	2
O	807	813	cycles
O	814	816	of
O	817	823	FEC100
O	824	827	and
O	828	837	switching
O	838	840	to
O	841	850	docetaxel
O	851	853	if
O	854	859	tumor
O	860	864	size
O	865	874	decreased
O	875	877	by
O	878	879	<
O	879	881	30
O	881	882	%
O	883	888	after
O	889	890	2
O	891	897	cycles
O	898	900	or
O	901	902	<
O	902	904	50
O	904	905	%
O	906	911	after
O	912	913	4
O	914	920	cycles
O	921	923	of
O	924	930	FEC100
O	931	932	(
O	932	942	ultrasound
O	943	954	assessments
O	955	964	according
O	965	967	to
O	968	973	World
O	974	980	Health
O	981	993	Organization
O	994	1002	criteria
O	1002	1003	)
O	1003	1004	.

O	1005	1014	Otherwise
O	1014	1015	,
O	1016	1022	FEC100
O	1023	1026	was
O	1027	1032	given
O	1033	1036	for
O	1037	1040	six
O	1041	1047	cycles
O	1048	1054	before
O	1055	1062	surgery
O	1062	1063	.

O	1064	1070	Intent
O	1070	1071	-
O	1071	1073	to
O	1073	1074	-
O	1074	1079	treat
O	1080	1088	analysis
O	1089	1092	was
O	1093	1102	performed
O	1102	1103	.

O	1104	1111	Similar
O	1112	1119	results
O	1120	1124	were
O	1125	1133	observed
O	1134	1137	for
O	1138	1146	clinical
O	1147	1155	response
O	1156	1157	(
B-outcome	1157	1166	objective
I-outcome	1167	1175	response
O	1176	1179	was
B-iv-bin-percent	1180	1182	54
I-iv-bin-percent	1182	1183	%
O	1184	1186	vs
B-cv-bin-percent	1187	1189	56
I-cv-bin-percent	1189	1190	%
O	1190	1191	,
O	1192	1193	p
O	1194	1195	=
O	1196	1197	.
O	1197	1199	18
O	1199	1200	)
O	1200	1201	,
B-outcome	1202	1208	breast
I-outcome	1209	1221	conservation
I-outcome	1222	1229	surgery
O	1230	1231	(
O	1231	1234	BCS
O	1234	1235	;
B-iv-bin-percent	1236	1238	67
I-iv-bin-percent	1238	1239	%
O	1240	1242	vs
B-cv-bin-percent	1243	1245	68
I-cv-bin-percent	1245	1246	%
O	1246	1247	,
O	1248	1249	p
O	1250	1251	=
O	1252	1253	.
O	1253	1255	97
O	1255	1256	)
O	1256	1257	,
O	1258	1261	and
B-outcome	1262	1274	pathological
I-outcome	1275	1283	complete
I-outcome	1284	1292	response
I-outcome	1293	1297	rate
O	1298	1299	(
B-outcome	1299	1309	Chevallier
I-outcome	1310	1324	classification
O	1324	1325	:
B-iv-bin-percent	1326	1328	14
I-iv-bin-percent	1328	1329	%
O	1330	1332	vs
B-cv-bin-percent	1333	1335	11
I-cv-bin-percent	1335	1336	%
O	1336	1337	,
O	1338	1339	p
O	1340	1341	=
O	1342	1343	.
O	1343	1345	68
O	1345	1346	;
B-outcome	1347	1355	Statloff
I-outcome	1356	1370	classification
O	1370	1371	:
B-iv-bin-percent	1372	1374	16
I-iv-bin-percent	1374	1375	%
O	1376	1378	vs
B-cv-bin-percent	1379	1381	13
I-cv-bin-percent	1381	1382	%
O	1382	1383	,
O	1384	1385	p
O	1386	1387	=
O	1388	1389	.
O	1389	1391	82
O	1391	1392	)
O	1393	1400	between
O	1401	1405	arms
O	1406	1407	A
O	1408	1411	and
O	1412	1413	B
O	1413	1414	.

O	1415	1422	Similar
B-outcome	1423	1433	toxicities
O	1434	1438	were
O	1439	1447	observed
O	1447	1448	,
O	1449	1453	even
O	1454	1458	with
O	1459	1469	unbalanced
O	1470	1477	numbers
O	1478	1480	of
O	1481	1487	FEC100
O	1488	1491	and
O	1492	1501	docetaxel
O	1502	1509	courses
O	1509	1510	.

O	1511	1518	Adapted
O	1519	1522	and
O	1523	1531	standard
O	1532	1542	treatments
O	1543	1546	had
O	1547	1554	similar
O	1555	1562	results
O	1563	1565	in
O	1566	1571	terms
O	1572	1574	of
O	1575	1580	tumor
O	1581	1589	response
O	1589	1590	,
O	1591	1594	BCS
O	1595	1599	rate
O	1599	1600	,
O	1601	1604	and
O	1605	1617	tolerability
O	1617	1618	.

O	1619	1626	Further
O	1627	1635	survival
O	1636	1643	outcome
O	1644	1648	data
O	1649	1652	are
O	1653	1661	expected
O	1661	1662	.
